Please login to the form below

Not currently logged in
Email:
Password:

Sales rep mirroring declines

Doctors can no longer deal with enormous numbers of sales reps vying for their time daily, so pharmaceutical companies have been cutting down on how many reps are responsible for calling on them, according to a Cutting Edge report.

Doctors can no longer deal with enormous numbers of sales reps vying for their time daily, so pharmaceutical companies have been cutting down on how many reps are responsible for calling on them, according to a Cutting Edge report.

The report, entitled "Pharmaceutical Sales Management 2008" publishes the results of a survey which revealed that fewer reps from each company currently call on an individual doctor, compared with two years ago.

The report says it was not unusual for the average high prescribing doctor to have more than four reps from each company visiting, but the average is now closer to three reps from each company per high value doctor.

The trend started when companies, such as Wyeth and Pfizer, instituted a strategy change to reduce the mirroring of reps in their field forces. The current study reveals that this strategy has spread to other companies as well.

The report, which is available in summary investigates pharmaceutical companies' sales investment, structure, strategies models and field tactics.

David Richardson, senior analyst at Cutting Edge Information, said: "When the dust started to settle toward the end of the pharmaceutical sales arms race, companies started hearing that many of the top doctors were unhappy that their waiting rooms had as many sales reps in them as patients."

"Sales leaders are responding to their targets by pulling back on their mirrored strategies and trying to get back to the more personal relationships that were the norm with doctors prior to the massive expansions that occurred in the last ten or so years," added Richardson.



28th September 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics